Update of research on the role of EZH2 in cancer progression

Liang Shen1
Jing Cui2
Shumei Liang3
Yingxin Pang1
Peishu Liu1

1Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 2Department of Oral and Maxillofacial Surgery, Jinan Stomatologic Hospital, 3Department of Obstetrics and Gynecology, Provincial Hospital Affiliated to Shandong University, Jinan, People’s Republic of China

Correspondence: Peishu Liu
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Wen Hua Xi Lu No 107, Jinan, Shandong 250012, People’s Republic of China
Tel +86 531 8216 9563
Fax +86 531 8692 7544
Email peishuliu1982@163.com

Abstract: Accumulating evidence shows that enhancer of zeste homolog 2 (EZH2) is upregulated in a broad range of cancer types, such as breast cancer, prostate cancer, ovarian cancer, and colon cancer. Therefore, inhibiting EZH2 expression may be a promising strategy for anticancer therapy. This review focuses on the current understanding of the mechanisms underlying EZH2 regulation that are involved in cancer progression. Also, it introduces two EZH2 inhibitors that target EZH2 and could be potentially applied in the treatment of cancer in the future.

Keywords: EZH2, PRC2, cancer

Introduction
Enhancer of zeste homolog 2 (EZH2) encodes a histone methyltransferase, which is the catalytic core protein of the polycomb repressor complex 2 (PRC2).1,2 PRC2 is well known for initiating target gene silencing by promoting H3K27 trimethylation, which is catalyzed by EZH2. Several articles implicated that the EZH2 is involved in the cell proliferation, invasion, apoptosis, angiogenesis, and metastasis of cancer progression.

Underlying mechanism of EZH2 in cancer progression
Polycomb group proteins maintain the gene expression pattern of different cells that is set during early development by modifying chromatin structure.1 In mammals, there are two main polycomb group complexes, PRC1 and PRC2. The PRC2 complex mainly consists of four core components: EZH2, suppressor of zeste 12 homolog (SUZ12), embryonic ectoderm development protein (EED), and retinoblastoma-associated protein 46/48. EZH2 via the SET domain catalyzes H3K27me3, and is associated with the silencing of tumor suppressor genes such as DAB2IP (Figure 1).4 Cancer stem cells are a subgroup of cancer cells with several features: unlimited self-renewal potential, tumorigenicity, and chemoresistance.5 Several papers showed that signal transducer and activator of transcription 3 (STAT3) and EZH2 are involved in the self-renewal, pluripotency, and proliferation of cancer stem cells.6 Akt-dependent Ser21 phosphorylation of EZH2 has been reported in breast cancer cells treated with insulin-like growth factor 1 or estrogen.7 Furthermore, Chen et al confirmed the c-Jun N-terminal kinase (JNK) regulation of STAT3 and link the JNK–STAT3–Akt signaling axis to the phosphorylation of EZH2.8 Suva et al provided evidence that direct downregulated transcriptional regulation of c-Myc by EZH2 may constitute a novel mechanism underlying glioblastoma cancer stem cell maintenance.9
Xu et al discovered that in the castration-resistant prostate there is another mechanism for EZH2 in prostate cancer. Genetic variations of the EZH2 gene are not responsible for there are eleven genetic variations in EZH2 in prostate cancer, lopetidase inhibitor 3 in prostate cancer cells. Their research provided another promising approach for the treatment of BRCA1-mutated breast cancers. They discovered that DZNep promotes an increase of Cdc25C, an essential player for G2/M checkpoint control. Puppe et al observed increased EZH2 protein levels in human BRCA1-deficient tumor sections compared with other breast tumors. Furthermore, they used the EZH2 inhibitor 3-deazaneplanocin (DZNep) to treat the BRCA1-deficient cancer cell and BRCA1-positive cancer cells. Their research provided another promising approach for the treatment of BRCA1-mutated breast cancers.

EZH2 in breast cancer
Overexpressed EZH2 has been reported as a biomarker of aggressive breast cancer and associated with invasion and cancer progression. EZH2 expression in 280 breast cancer patients was tested by high-density tissue microarray. EZH2 levels were elevated in patients with invasive breast carcinoma compared with normal or atypical hyperplasia. Furthermore, it has been shown that high levels of EZH2 are associated with poor outcome to tamoxifen therapy in advanced breast cancer. Recently, EZH2-mediated epigenetic repression of DNA damage repair in breast tumor initiating cells was identified as a mechanism that could promote expansion of breast tumor initiating cells, and may contribute to cancer progression. To analyze the role of EZH2 in the molecular subtypes of breast tumors (basal-like, luminal A, luminal B, human epidermal growth factor 2 (HER2)-enriched, and normal-like), Holm et al tested the EZH2 and H3K27me3 expression in more than 400 tumors using immunohistochemistry. They found significantly high abundance of EZH2 in basal-like, triple negative, and HER2-enriched tumors, and high H3K27me3 in luminal A, HER2-enriched, and normal-like tumors. EZH2 overexpression inhibits breast cancer type 1 susceptibility protein (BRCA1) phosphorylation (Ser1423) and thereby promotes an increase of Cdc25C, an essential player for G2/M checkpoint control.

Roles of EZH2 in cancer
The accumulated finding is that EZH2 levels are abnormally elevated in cancer tissues compared with corresponding normal tissues. Furthermore, higher EZH2 levels are correlated with advanced stages of disease and poor prognosis.

EZH2 in prostate cancer
Analyses of patient samples significantly correlate abnormally elevated EZH2 levels with increased proliferation rates, invasiveness, and metastasis of prostate cancer. Van Leenders et al showed that expression of EZH2 was significantly enhanced in tumors with Gleason score of more than eight, extraprostatic extension, positive surgical margins, and prostate-specific antigen recurrence. Bryant et al found that knockdown of endogenous EZH2 reduced proliferation and invasion in prostate cancer cells. Furthermore, Ren et al indicated that EZH2 promoted prostate cancer cell invasion and metastasis via the repression of RIKIP, a metastasis suppressor gene. It is known that metastasis is associated with the balance between matrix metalloproteinases and their inhibitors, ie, tissue inhibitor of metalloproteinases. Shin et al discovered that EZH2 plays an active role in this process by repressing the expression of metallopeptidase inhibitor 2 and metallopeptidase inhibitor 3 in prostate cancer cells. Although, there are eleven genetic variations in EZH2 in prostate cancer, genetic variations of the EZH2 gene are not responsible for the linkage of 7q to aggressive prostate cancer. However, there is another mechanism for EZH2 in prostate cancer. Xu et al discovered that in the castration-resistant prostate cancer cells, EZH2 could be a transcriptional coactivator of androgen receptor instead of a transcriptional repressor of PCR2. Furthermore, their study demonstrates that the phosphatidylinositol 3-kinase-Akt pathway could mediate phosphorylation of EZH2 at Ser21 and this phosphorylation could be involved in the transcriptional coactivator.
estrogen receptor-negative cells, EZH2 activates nuclear factor-kB target genes by formation of a ternary complex with the nuclear factor-kB components RelA and RelB.23

EZH2 in ovarian cancer
Several authors have indicated that EZH2 is involved with invasion and metastasis in ovarian carcinoma. Rao et al found that high expression of EZH2 was found in none of the normal ovaries, in 3% of the cystadenomas, in 23% of the borderline tumors, and in 50% of the ovarian carcinomas.24 Drug resistance is a major clinical obstacle for ovarian cancer therapy. Rizzo et al found that EZH2 played a key role in the maintenance of a drug-resistant, tumor-sustaining subpopulation of cells in ovarian cancers undergoing chemotherapy.25 Furthermore, ALDH1A1 – a putative marker for epithelial ovarian cancer stem cells – is found as a novel EZH2 target gene in epithelial ovarian cancer cells.26 Lu et al identified EZH2 as a key regulator of tumor angiogenesis in ovarian cancer.27 In endothelial cells, vascular endothelial growth factor stimulation could lead to increased expression of E2F transcription factors, which directly mediate EZH2 levels. Then, EZH2 causes the silence of VASH1 – an anti-angiogenic gene – and subsequently increases angiogenesis.

EZH2 in non-small-cell lung cancers
Kikuchi et al analyzed the immunohistochemical assessment of 157 surgically resected non-small-cell lung cancers.28 They found that high EZH2 expression significantly correlated with non-adenocarcinoma histology, moderate and poor differentiation, advanced pathologic tumor classification, and high Ki-67 and cyclin E. Furthermore, Huqun et al found that positive EZH2 expression was associated significantly with larger tumor size in non-small-cell lung cancer.29 Kaplan–Meier survival analyses and logrank tests demonstrated that patients whose samples were classified into the positive EZH2 expression group had a significantly shorter overall survival. The mechanisms of EZH2 in the progression of non-small-cell lung cancer are not clear. A recent published paper shows that mir-138 – a novel tumor suppressor micro-RNA – is differentially expressed with non-adenocarcinoma histology, moderate and poor differentiation, advanced pathologic tumor classification, and nuclear factor-kB.

Potential cancer therapy function
It is known that EZH2 plays an important role in cancer development. EZH2 expression can be reduced with S-adenosylhomocysteine hydrolase inhibitor DZNep, which inhibits methyltransferases and induces degradation of EZH2, SUZ12, and EED as well as the associated H3K27me3. DZNep treatment was shown to result in reactivation of EZH2 repressed target genes, inhibited cell growth, and reduced tumor formation in various cancers.31 For example, Fiskus et al found that treatment with DZNep induced p16, p21, p27, and F-box protein 32 while depleting cyclin E and homeobox A9 levels in the cultured human acute myeloid leukemia cells and in primary acute myeloid leukemia cells.32 Furthermore, combined with gemcitabine, DZNep synergistically enhanced the antiproliferative activity of gemcitabine, reduced the percentage of cells in the G2/M phase, and significantly increased apoptosis.33 Recently, McCabe et al discovered a potent, highly selective, S-adenosylmethionine-competitive, small molecule inhibitor called GSK126. GSK126 can effectively inhibit the proliferation of EZH2 mutant diffuse large B-cell lymphoma cell lines and significantly inhibit the growth of EZH2 mutant diffuse large B-cell lymphoma xenografts in mice.34

Conclusion
This review highlights that overexpression of EZH2 is correlated with cell proliferation, invasion, adhesion, and metastasis in several cancer types. Inhibitors of EZH2, including DZNep and GSK126, seem very promising anticancer agents to help reach the ultimate goal of cancer prevention and remission.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science. 2002;298(5595):1039–1043.
2. Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol. 2011;24(6):786–793.
3. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343–349.
4. Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kB. Nat Med. 2010;16(3):286–294.
5. Crea F, Mathews LA, Farrar WL, Hurt EM. Targeting prostate cancer stem cells. Anticancer Agents Med Chem. 2009;9(10):1105–1113.
6. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer. 2012;106(2):243–247.
7. Cha TL, Zhou BP, Xia W, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005;310(5746):306–310.
8. Chen B, Liu J, Chang Q, Beezhold K, Lu Y, Chen F. JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic. Cell Cycle. 2013;12(1):112–121.
9. Suva ML, Riggi N, Janiszewska M, et al. EZH2 is essential for glioblastoma stem cell maintenance. Cancer Res. 2009;69(24):9211–9218.
van Leenders GJ, Dukers D, Hessels D, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. *Eur Urol* 2007; 52(2):455–463.

Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunilffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. *Prostate*. 2007;67(5):547–556.

Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. *Cancer Res*. 2012;72(12):3091–3104.

Shin YJ, Kim JH. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. *PLoS One*. 2012;7(1):e30393.

Bachmann N, Hoegel J, Haeusler J, et al. Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer. *Prostate*. 2005;65(3):252–259.

Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. *Science*. 2012;338(6113):1465–1469.

Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proc Natl Acad Sci U S A*. 2003;100(20):11606–11611.

Reijm EA, Jansen MP, Ruigrok-Ritstier K, et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. *Breast Cancer Res Treat*. 2011;125(2):387–394.

Stefansson OA, Esteller M. EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells. *Breast Cancer Res Treat*. 2011;13(3):309.

Holm K, Grabau D, Lovgren K, et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. *Mol Oncol*. 2012;6(5):494–506.

Gonzalez ME, Li X, Toy K, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. *Oncogene*. 2009;28(6):843–853.

Puppe J, Drost R, Liu X, et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to polycomb repressive complex 2 inhibitor 3-deazaneplanocin A. *Breast Cancer Res*. 2009;11(4):R63.

Shen et al

OncoTargets and Therapy

Publish your work in this journal

*OncoTargets and Therapy* is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.

*OncoTargets and Therapy* is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal

Shen et al

OncoTargets and Therapy

Publish your work in this journal

*OncoTargets and Therapy* is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal

Dovepress

324

Dovepress

OncoTargets and Therapy 2013:6